<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab00083">
 <label>Table 8.3</label>
 <caption>
  <p>Phase I human clinical trials with NVCP VLP-based vaccines</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Production system</th>
    <th>Number of volunteers</th>
    <th>Formulation</th>
    <th>Number of doses and dosage range</th>
    <th>Delivery route</th>
    <th>Immunogenicity</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center">Insect cell/baculovirus</td>
    <td align="center">20</td>
    <td align="center">Water, no adjuvant</td>
    <td align="center">Two doses of 100–250 μg at days 1 and 21</td>
    <td align="center">Oral</td>
    <td>Serum IgG and IgA responses were dose-dependent and NV-specific tilters increased at least four-fold in 100 % of volunteers in the 250 μg group. 83 % responded in serum IgG titers after the first VLP dose and showed no increase after the second dose [
     <xref ref-type="bibr" rid="CR0008147">147</xref>]
    </td>
   </tr>
   <tr>
    <td align="center">Insect cell/baculovirus</td>
    <td align="center">36</td>
    <td align="center">Water, no adjuvant</td>
    <td align="center">Two doses of 250, 500, and 2,000 μg at days 1 and 21</td>
    <td align="center">Oral</td>
    <td>Increase of NV-specific IgG titers was detected in 90 % of participants in the 250 μg group. No further increase in the rates of seroconversion or IgG titers for the 500 and 2,000 μg groups. Increase of NV-specific IgA ASC numbers in 100 % of vaccinated volunteers was observed and 30–40 % of volunteers developed salivary, fecal, or genital fluid IgA antibody [
     <xref ref-type="bibr" rid="CR0008144">144</xref>]
    </td>
   </tr>
   <tr>
    <td align="center">Insect cell/baculovirus</td>
    <td align="center">28</td>
    <td align="center">Dry power with chitosan, MPL as adjuvant</td>
    <td align="center">Two doses of 5, 15, and 50 μg at days 0 and 21</td>
    <td align="center">IN</td>
    <td>Serum IgG and IgA responses were dose dependent with their titers increased 4.7 and 4.5 folds, respectively, for the 50 μg group. 53 % of subjects developed rises in NV-specific IgA ASCs [
     <xref ref-type="bibr" rid="CR0008148">148</xref>]
    </td>
   </tr>
   <tr>
    <td align="center">Insect cell/baculovirus</td>
    <td align="center">61</td>
    <td align="center">Dry power with chitosan, MPL as adjuvant</td>
    <td align="center">Two doses of 50 and 100 μg at days 0 and 21</td>
    <td align="center">IN</td>
    <td>63 and 79 % of vaccinated subjects in the 100 μg group increased IgG and IgA titers by 4.8- and 9.1-folds, respectively. The IgG and IgA titers of the 100 μg group are higher than the 50 μg group, but not statistically different. All vaccinated individuals in the 50 and 100 μg groups developed IgA ASCs. Homing molecules to mucosal and peripheral lymphoid tissues were detected on these ASCs [
     <xref ref-type="bibr" rid="CR0008148">148</xref>]
    </td>
   </tr>
   <tr>
    <td align="center">Transgenic potato</td>
    <td align="center">20</td>
    <td align="center">Raw potato tuber
     <sup>a</sup>
    </td>
    <td align="center">Two or three doses of 215–751 μg in 150 g potato tuber
     <sup>a</sup> at days 0 and 21 or at days 0, 7,and 21
    </td>
    <td align="center">Oral</td>
    <td>20 and 30 % of vaccinated volunteers developed NV-specific serum IgG (12-fold rise) and fecal IgA (17-fold increase), respectively. 95 % of subjects developed NV-IgA ASCs [
     <xref ref-type="bibr" rid="CR0008149">149</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>IN</italic> intranasal, 
   <italic>ASCs</italic> antibody-secreting cells
  </p>
  <p>
   <sup>a</sup>Each 150 g of raw potato tuber contained between 215 and 751 μg variable amounts of NVCP antigen
  </p>
 </table-wrap-foot>
</table-wrap>
